AstraZeneca PLC  (AZN) Trade Now »     Rate AZN  -  Discuss AZN  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

AZN: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Analyst Recommendation AZN

N/A

-0.78% in 72 days New AstraZeneca drug reduces heart patients' risks AstraZeneca says Brilinta anti-clotting drug reduces chance of dying better than Plavix By Maria Cheng, AP Medical Writer On Sunday August 30, 2009, 1:45 pm EDT BARCELONA, Spain (AP) -- A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008. About half the patients were taking clopidogrel, also known as Plavix, while the other half were taking an experimental... Continue reading »

FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR AZN

73%

+4.41% in 133 days <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st... Continue reading »

FDA Calendar Updates at BioMedReports.com AZN

73%

-2.24% in 5 days (closed on 06/30/09) <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st... Continue reading »

FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO AZN

73%

+7.89% in 25 days (closed on 06/25/09) <> Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete respon... Continue reading »

FDA, Clinical Trial Calendar Updates: AZN, IMGN, MIPI, MELA AZN

73%

+9.36% in 20 days (closed on 05/31/09) <> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo... Continue reading »

From the Blogosphere

Big Pharma and Biotech – Industry Outlook

38%

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co... Continue reading »

Zacks #1 Rank Additions for Monday – Zacks Tale of the Tape

38%

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today: <> Aircastle Ltd (AYR) AMICAS Inc (AMCS) AstraZeneca Plc (AZN) Cantel Medical Corp (CMN) Coherent Inc (COHR) Dover Motorsports Inc (DVD) Euronet Worldwide Inc (EEFT) Gannett Co Inc (GCI) Herbalife Ltd (HLF) International Flavors & Fragrances Inc (IFF) Kadant Inc (KAI) Lincoln Educational Services Corp (LINC) Lionbridge Technologies Inc (LIOX) Nu Skin Enterprises Inc (NUS) OSI Systems Inc (OSIS) Penske Auto Group Inc (PAG) Pinnacle Airlines Corp (PNCL) <><>Pioneer Southwes... Continue reading »

Analyst upgrades, downgrades and initiations: ANF, AZN, BX, GPS, PH, RAIL, VRSN ...

Filed under: Analyst reports, Analyst upgrades and downgrades, Analyst initiations Analyst upgrades: <> Keefe Bruyette upgraded Blackstone Group (BX) to outperform from market perform following the company's Q3 results and maintains an $18.50 price target on shares. Baird upgraded Astec (ASTE) to outperform from neutral citing relative valuation and upside from new multi-year U.S. highway funding legislation. The firm raised its target to $33 from $27. <>Goldman upgraded Abercrombie & Fitch (ANF) to conviction buy from neutral citing "significant" long-term growth drivers that include ... Continue reading »

Watson Pharma Beats by a Penny – Analyst Blog

38%

Watson Pharmaceuticals, Inc. (WPI) reported third quarter earnings of 66 cents per share, a cent above the Zacks Consensus Estimate. Margin improvements resulting from operating efficiencies achieved through the company’s Global Supply Chain Initiative and contributions from new products helped increase earnings by 40% from the year-ago period. Revenues increased 3% to $662.1 million. The Generic product division posted sales of $392.3 million, up 11%. The increase was driven by contributions from new products like the generic version of AstraZeneca’s (AZN) Toprol XL (potassium-chloride ... Continue reading »

H1N1: How to Buy into the Fear

<>The whole world seems to be fixated on the economy and the H1N1 Swine Flu. News reports yesterday that the first shipments of the nasal version of the vaccine, manufactured by MedImmune, a unit of AstraZeneca (AZN), will begin Tuesday pushed me to find out if there might be an investing play in this fear. The major manufacturers of the vaccine are GlaxoSmithKline (<font>GSK</font>), Sanofi-Aventis (<font>SNY</font>), Novartis (<font>NVS</font>), AstraZeneca (<font>AZN</font>), Baxter Intl (<font>BAX</font>) and CSL Ltd (<font>CMXHY.PK</font>). None of these are pure plays. Each of these com... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.